TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01097967

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPAP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Study: NCT02786082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg Azilsartan Tablets
Description: Strength: 20mg, oral administration 1 tablet/ day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg Azilsartan Tablets
Description: Strength: 40mg, oral administration 1 tablet/ day
Study: NCT02732366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based exercise and peer coaching
Description: Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual PT and attention control grp class
Description: The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
Study: NCT04682496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intratendon vascularization
Description: Ultrasonic exploration by power-Doppler of the intratratendon vascularization, making longitudinal cuts of the patellar tendon and with previously pre-established Doppler optimization parameters for all patients. The optimization parameters of the power-Doppler signal will be set at a Doppler frequency of 6.7 MHz, pulse repetition frequency (PRF) of 0.7 kHz. The lowest wall filter and a standardized gain just below the level that produces random noise will be applied. This examination will be repeated several times with different probe pressures, which will be quantitatively adjusted through the force sensor and maintained with the articulated arm. A 4-second static video will be recorded of the longitudinal section that presents a higher Doppler signal in each of the scans at different probe pressures.
Study: NCT02191982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk With Ease
Description: Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walk With Ease
Description: Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
Study: NCT00788996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention based in clinical practice guide
Description: Minimal counseling at smoking parents with babies minor 1 year-old
Study: NCT04484467

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement With Standardized Menthol, Limonene, and Ginger
Description: Components of Standart Zdorovya GASTRO: Peppermint oil (40% menthol, 1.5% limonene) - 240 mg, Ginger oil (14% gingerol) - 50 mg, olive oil - 440 mg, 1 capsule, 730 mg, once a day for 30 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Components of placebo Olive oil - 730 mg, 1 capsule, 730 mg, once a day for 30 days
Study: NCT02235948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid supplementation
Description: 0.8mg folic acid/day
Study: NCT04189562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Intervention
Description: Delivery of text messages will use the text messaging program Simple Online Family Intervention for ADHD (SOFIA).
Study: NCT02959996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: liposomal bupivacaine injection in the Pfannenstiel incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injection in the Pfannenstiel incision
Study: NCT00722761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drospirenone and ethinyl estradiol
Description: Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (no active drug) given once daily for 24 weeks
Study: NCT02393794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Histone deacetylase inhibitor
Study: NCT01702220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 6-12 sessions of CBT in person or over the phone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECC
Description: 6 biweekly sessions of ECC over the telephone
Study: NCT02503124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single night's wake therapy
Description: Eligible patients are assisted in maintaining total sleep deprivation during one night

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Bright light according to patients´ own circadian rhythm each morning for a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual - inpatient care
Description: All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual - inpatient care
Description: All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative meeting
Description: A short sleep hygiene consultation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual - medicine
Description: Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual - medicine
Description: Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
Study: NCT02368223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YouGrabber
Description: 2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
Study: NCT02149979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temperature Controlled Laser Soldering
Description: This study had a prospective within-subject design. Patients allocated to laparoscopic cholecystectomy procedure were enrolled. After the completion of the laparoscopic cholecystectomy surgical procedure, 4 trocar port sites were randomly either sutured or laser soldered by employing the temperature-controlled laser soldering system.
Study: NCT01976429

Intervention type: OTHER
Group type: OTHER
Intervention: flight/diving simulation
Description: measurement of ET function during simulated flight/diving in pressure chamber

Intervention type: OTHER
Group type: OTHER
Intervention: flight/diving simulation
Description: measurement of ET function during simulated flight/diving in pressure chamber

Intervention type: OTHER
Group type: OTHER
Intervention: ET function testing at ambient pressure
Description: ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence

Intervention type: OTHER
Group type: OTHER
Intervention: ET function testing at ambient pressure
Description: ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence

Intervention type: OTHER
Group type: OTHER
Intervention: nasal video-endoscopy
Description: examination of nose, nasopharynx,and Eustachian tube orifice
Study: NCT05311059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling
Description: Drilling needle was introduced and connected by monopolar current, held against ovarian surface for 4 seconds using a power of 40 watt, 4 puncture was done in each ovary with putting into consideration that the puncture must be not superficial and it must go deep through the main substance of the ovary
Study: NCT02514720

Intervention type: OTHER
Group type: OTHER
Intervention: cigarette
Description: Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan

Intervention type: OTHER
Group type: OTHER
Intervention: cigarette
Description: Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
Study: NCT03355274

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous Oximetry
Description: The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up).

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Oximetry
Description: The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Photopletysmography
Description: Maneuvers are repeted with the photoplestysmography sensors and in front of a Kinect camera.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Photopletysmography
Description: Maneuvers are repeted with the photoplestysmography sensors and in front of a Kinect camera.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires of Quality of Life (QoL)
Description: Each subject complete 2 QoL questionnaires : Sf-12 (Short Form 12) and DASH (Disabilities of the Arm, Shoulder and Hand).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires of Quality of Life (QoL)
Description: Each subject complete 2 QoL questionnaires : Sf-12 (Short Form 12) and DASH (Disabilities of the Arm, Shoulder and Hand).
Study: NCT01686672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Intervention
Description: Behavioral
Study: NCT03522012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.
Study: NCT03136237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Day 1 of Cohort 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353 + digoxin
Description: Day 19 of Cohort 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Day 1 of Cohort 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin + BCX7353
Description: Day 15 of Cohort 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine + BCX7353
Description: Day 14 of Cohort 3
Study: NCT04620837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab：200mg Q3W IV. There will be no dose reduction for Tislelizumab ， if there is no disease progression or serious Treatment Related adverse events(TRAE) , patients will receive Tislelizumab (200mg,Q3W) until progression or death

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated. Depending tolerated dose reduction. Medication process: disease control and patients can tolerate the side effects, continued drug use; researchers believe the patient is not fit to continue medication or efficacy evaluation at the end of the clinical progression of medication.
Study: NCT03803007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ACT017 1000 mg
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Study: NCT00318474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMF Placebo
Description: Placebo only, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACEi
Description: Administer same as pre-treatment regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEi
Description: Administer same as pre-treatment regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOS
Description: Administer same as pre-treatment regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOS
Description: Administer same as pre-treatment regimen
Study: NCT01297517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide ophthalmic suspension, 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution, 0.2%
Study: NCT02484846

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time in bed
Description: Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time in bed
Description: Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time in bed
Description: Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time in bed
Description: Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time in bed
Description: Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time in bed
Description: Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time in bed
Description: Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
Study: NCT02462772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabotegravir
Description: Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
Study: NCT01996241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level, structural and norms-based intervention
Description: Receive multi-level, structural and norms-based intervention
Study: NCT03155464

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Order of two elements of surgical procedure
Description: Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Order of two elements of surgical procedure
Description: Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Description: Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Description: Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
Study: NCT00302380

Intervention type: RADIATION
Intervention: PET imaging using C-11 altropane as the ligand.
Description: A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.

Intervention type: RADIATION
Intervention: PET imaging using C-11 altropane as the ligand.
Description: A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
Study: NCT02752113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin and Linagliptin
Description: Empagliflozin and Linagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Insulin sc
Description: Metformin and Insulin sc
Study: NCT00092118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: one 10 mg tablet, taken once daily at bed time for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: one placebo tablet, taken once daily at bed time for 6 weeks